Hoth Therapeutics, Inc.

NasdaqCM:HOTH Stock Report

Market Cap: US$12.5m

Hoth Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Robb Knie

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage36.7%
CEO tenure8yrs
CEO ownership0.4%
Management average tenure6.2yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Nov 12
Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Jun 10
We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

CEO Compensation Analysis

How has Robb Knie's remuneration changed compared to Hoth Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$1mUS$450k

-US$8m

Sep 30 2024n/an/a

-US$8m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$846kUS$450k

-US$8m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$1mUS$450k

-US$11m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$400k

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$781kUS$350k

-US$7m

Sep 30 2020n/an/a

-US$10m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$2mUS$350k

-US$8m

Sep 30 2019n/an/a

-US$4m

Jun 30 2019n/an/a

-US$3m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$308kUS$250k

-US$2m

Compensation vs Market: Robb's total compensation ($USD1.23M) is above average for companies of similar size in the US market ($USD679.45K).

Compensation vs Earnings: Robb's compensation has increased whilst the company is unprofitable.

CEO

Robb Knie (55 yo)

8yrs

Tenure

US$1,226,792

Compensation

Mr. Robb Knie is Founder of Hoth Therapeutics, Inc. Mr. Knie served as the Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors of FoxWayne Enterprises Acquisition Corp....

Leadership Team

NamePositionTenureCompensationOwnership
Robb Knie
Founder8yrsUS$1.23m0.44%
$ 55.4k
David Briones
Chief Financial Officer6.2yrsno datano data
Hayley Springer
Executive Vice President of Operations3yrsno datano data

6.2yrs

Average Tenure

Experienced Management: HOTH's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robb Knie
Founder8yrsUS$1.23m0.44%
$ 55.4k
Adam Friedman
Member of Scientific Advisory Board7.8yrsno datano data
Mario Lacouture
Member of Scientific Advisory Board4.3yrsno datano data
David Sarnoff
Independent Director6.8yrsUS$93.36k0.0076%
$ 952.3
William Weglicki
Member of Scientific Advisory Board5.4yrsno datano data
Wayne Linsley
Independent Director5.1yrsUS$93.36k0.0010%
$ 128.0
Glenn Cruse
Member of Scientific Advisory Board5.3yrsno datano data
Sergio Traversa
Member of Scientific Advisory Boardno datano datano data
Jeff Pavell
Independent Director2.4yrsUS$93.36k0.039%
$ 4.8k
John Cirrito
Member of Scientific Advisory Board3.3yrsno datano data
Carla Yuede
Member of Scientific Advisory Board3.3yrsno datano data

5.2yrs

Average Tenure

56yo

Average Age

Experienced Board: HOTH's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 16:17
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hoth Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Jason KolbertD. Boral Capital LLC.
Raghuram SelvarajuH.C. Wainwright & Co.